|
|
Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors
| Third-party funded project |
| Project title |
Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors |
| Principal Investigator(s) |
Hall, Michael N.
Maier, Timm
|
| Organisation / Research unit |
Departement Biozentrum / Structural Biology (Maier),
Departement Biozentrum / Biochemistry (Hall) |
| Department |
Departement Biozentrum |
| Project start |
01.07.2022 |
| Probable end |
30.06.2024 |
| Status |
Active |
| Abstract |
Laufzeit 01.04.2022-31.01.2024
Increased activity of mammalian target of rapamycin complex 1(mTORC1) is linked to multiple disorders. We identified ten small compounds that selectively and efficiently inhibit mTORC1 in vitro with an innovative mode of action. We now aim to achieve precinlincal proof of mechanism in mice. |
| Financed by |
Innovation Promotion Agency CTI
|
| |
|
|
MCSS v5.8 PRO. 0.403 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
20/04/2024
Research Database / FORSCHUNGSDATENBANK
|
